Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Jonathan Meyer, MD

This presentation is provided by Teva Pharmaceuticals USA, Inc.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Heather Luing, MD; Desiree Matthews, PMHNP-BC

This presentation is provided by Bristol Myers Squibb.

Additional fees apply and pre-registration is required.

Technology is rapidly transforming psychiatric care, offering new tools for diagnosis, treatment, and patient engagement—but for many clinicians, navigating these innovations can feel overwhelming. This interactive, hands-on preconference is designed to demystify digital psychiatry, providing attendees with practical strategies to integrate technology into their everyday practice. Through a combination of live demonstrations, case-based discussions, and expert panels, attendees will explore essential digital tools, the latest in AI-assisted decision support, and best practices for telepsychiatry and digital therapeutics. The day will culminate with a future-focused keynote, exploring what’s next in digital mental health and how clinicians can stay ahead of emerging trends.

Topics to be covered:

Digital Tools in Psychiatry—What’s Essential? Interactive Workshop: Exploring the Latest Digital Tools for Mental Health Overcoming Barriers & Ethical Considerations Fireside Chat: Bridging the Future of Tech and Psychiatry

Additional fees apply and pre-registration is required.

This year’s Advanced Psychopharmacology Preconference provides a deep dive into four emerging mechanisms of action (MOAs) that are reshaping psychiatric treatment. As research continues to expand beyond traditional neurotransmitter targets, new pathways are offering innovative solutions for mood disorders, agitation, sleep disturbances, and treatment resistance. This year’s preconference will explore the science behind these novel treatment approaches, their clinical applications, and the practical considerations for integration into psychiatric practice. Each session will feature an expert-led discussion, followed by an interactive Q&A to ensure attendees gain actionable insights into how these next-generation treatments can enhance patient outcomes.

Topics to be covered:

Glutamate-Based Treatments Muscarinic-Based Treatment Advances Orexin-Based Treatments Mechanisms in the Making: What’s Next in Mood Disorder Pharmacology?

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Gus Alva, MD, DLFAPA; Larry H. Lambertson, MD, CMHC; Patient and Patient's Care Partner

This presentation is provided by Bristol Myers Squibb.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Greg Mattingly, MD

This presentation is provided by Otsuka America Pharmaceutical, Inc. and Lundbeck.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Birgit Amann, MD; Rakesh Jain, MD, MPH

This presentation is provided by Supernus Pharmaceuticals, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
David Scheiderer, MD

This presentation is provided by AbbVie.

Dr. Vladimir Maletic’s impact on psychiatry was as scientific as it was deeply personal. He was a pioneer in psychopharmacology, a brilliant educator, and a healer who never gave up on his patients. This session will celebrate his contributions to the field, the principles that guided his practice, and the ripple effect of his mentorship on clinicians and patients alike. Through case studies, video tributes, and personal reflections from faculty and former patients, we will explore the enduring lessons of his work—how to practice with both knowledge and heart, how to balance science with intuition, and how to never stop advocating for patients' well-being.

Despite being one of the most prevalent and deadly substance use disorders, Alcohol Use Disorder (AUD) often remains underrecognized and undertreated in psychiatric settings. This session will provide a comprehensive, practical guide to treating AUD, with a focus on medication management in patients who continue to drink, harm reduction strategies, and emerging digital health interventions. Faculty will also discuss smart referral practices and interdisciplinary care coordination to improve outcomes in patients with complex needs.

Lithium remains a cornerstone in mood disorder treatment, offering unparalleled efficacy for bipolar disorder and suicidality. Yet, its use requires precision in dosing, monitoring, and side effect management. This session will explore the latest insights into lithium’s mechanisms, therapeutic benefits, and best practices for clinical use. Faculty will also discuss strategies for maintaining adherence, mitigating toxicity risks, and navigating lithium use in special populations.

With rapid advancements in Alzheimer’s disease treatment, new therapeutic options are reshaping how clinicians approach disease management. This session will provide a comprehensive update on emerging pharmacologic interventions, including anti-amyloid and anti-tau immunotherapies, as well as novel symptomatic treatments. Faculty will explore the clinical implications of these breakthroughs, addressing real-world considerations such as treatment selection, safety monitoring, and long-term care strategies for patients with Alzheimer's.

Session developed in partnership with the American Association for Geriatric Psychiatry (AAGP).

Schizophrenia management is rarely straightforward—treatment resistance, severe agitation, and overlapping psychiatric and medical conditions often complicate care. In this case-based session, expert faculty will confront real-world, high-stakes scenarios that challenge conventional treatment models. Panelists will collaborate, debate, and be put on the spot to answer the ultimate question: What would you do? Attendees will walk away with innovative, patient-centered, and multidisciplinary strategies to tackle their most difficult cases.

Coffee will be served in the Ballroom 20 Foyer.

Sleep and mental health are deeply intertwined, yet sleep/wake disorders often go underrecognized in psychiatric settings. This session will explore the neurobiological and clinical interplay between psychiatric conditions and sleep disturbances, highlighting the bidirectional impacts on patient well-being. Attendees will examine how psychiatric and sleep medications influence one another and learn practical strategies to enhance the detection and differential diagnosis of sleep/wake disorders. The session will also emphasize the value of interdisciplinary collaboration with sleep specialists, equipping psychiatry clinicians with actionable insights to deliver more comprehensive, integrated care. Supported by educational grants from Alkermes, Inc. and Harmony Biosciences. Developed in partnership with the Sleep Research Society Foundation.

Agitation in Alzheimer’s disease (AAD) presents significant challenges in diagnosis and management, often exacerbating caregiver burden and accelerating disease progression. This session will explore the clinical framework and neurobiological underpinnings of AAD, while providing practical strategies and tools to enhance the recognition and assessment of agitation across its full behavioral spectrum. The session will also examine the latest clinical data and mechanisms of action for novel and investigational therapies, offering insights into emerging treatment options and their potential to reshape care for patients with Alzheimer’s-related agitation. Supported by an educational grant from Axsome Therapeutics, Inc. Developed in partnership with Caregiver Action Network.

For many patients with major depressive disorder (MDD), first-line antidepressant therapy yields only partial relief. Timely recognition and strategic augmentation are required to achieve a better result. This session will guide clinicians through the identification of inadequate treatment responses and the critical decision points for initiating adjunctive therapy. Attendees will explore the mechanisms of action and latest clinical data on FDA-approved and emerging atypical antipsychotics (AAPs) used in combination treatment. Practical guidance will also be provided on selecting among adjunctive options and addressing real-world barriers to their effective implementation in psychiatric practice. Supported by educational grants from AbbVie Inc. and Intra-Cellular Therapies, Inc.

For decades, the number of patients living with psychotic illness who are experiencing homelessness and criminal legal involvement have been skyrocketing. This keynote explores how policy, neuroscience, and neuroethics can inform improvements in those outcomes. California’s CARE Court, global models from Italy, and emerging neuroethical considerations offer a path forward. Led by a distinguished panel of experts in policy, medicine, and ethics, this session will challenge outdated paradigms and present a vision for early, ethical, and effective psychiatric care. 

Join the Psych Congress Steering Committee, attendees, and peers for a the keynote reception with hors d'oeuvres and beverages.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Andrew Cutler, MD; Joel Young, MD

This presentation is provided by Tris Pharma.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Richard W. Miller, MD

This presentation is provided by Johnson & Johnson.

The connection between inflammation and depression is reshaping treatment paradigms. This session will unpack the latest research on immune system dysregulation in MDD, explore the role of IL-6 inhibitors, dietary modifications, and lifestyle interventions, and discuss how inflammation-targeting strategies could revolutionize depression treatment. Gain insights into the clinical applicability of inflammation-targeting treatments and their role in personalized medicine.

Technology is both a tool for well-being and a source of stress, creating a paradox for clinicians and patients alike. While digital platforms enhance connection, productivity, and access to mental health resources, excessive use can contribute to anxiety, attention difficulties, sleep disturbances, and emotional overload. This session will explore practical strategies to help patients (and clinicians) find balance in a hyperconnected world, addressing the psychological impact of digital overuse, strategies for managing screen time, and evidence-based approaches to fostering a healthier relationship with technology.

Alzheimer’s prevention is no longer theoretical—emerging research shows that modifiable lifestyle factors can significantly impact cognitive aging. This session will present the latest data on brain-healthy habits, early detection, and clinical strategies for reducing dementia risk.

Session developed in partnership with the American Association for Geriatric Psychiatry (AAGP) and Caregiver Action Network (CAN).

Breakthrough research in schizophrenia and other psychotic disorders is shaping the future of treatment, diagnosis, and prevention. This session will provide a fast-paced, research-focused deep dive into the most significant discoveries of the past year, featuring expert analysis alongside selected poster presenters unveiling emerging data. Faculty will discuss the latest advancements, offering insight into how these findings may change the way clinicians approach psychotic disorders.

True remission in MDD and bipolar disorder requires more than symptom reduction—it demands functional recovery. This session will explore strategies to restore daily functioning, improve productivity, and support long-term well-being, addressing how recovery goals differ between the two conditions. Faculty will highlight lifestyle interventions such as exercise, nutrition, sleep hygiene, and stress management, alongside evidence-based pharmacologic and psychological treatments to help patients thrive beyond symptom relief.

Session developed in partnership with the Depression and Bipolar Support Alliance.

Coffee will be served in the Ballroom 20 Foyer.

Sleep-wake disorders like narcolepsy are often under recognized in psychiatric practice, despite their frequent comorbidity with mood, anxiety, and attention-related conditions. This session explores the neurobiological underpinnings of narcolepsy and highlights its diagnostic and therapeutic relevance in psychiatric care. Attendees will learn strategies for improving detection in patients with overlapping psychiatric symptoms and gain clarity on the collaborative role of psychiatric clinicians alongside sleep specialists. The session will also delve into the latest advances in orexin receptor agonism, including novel mechanisms of action and emerging clinical data that may soon reshape treatment for narcolepsy and related disorders. Supported by an educational grant from Takeda Pharmaceuticals, U.S.A. Developed in partnership with the Sleep Research Society Foundation.

Bipolar disorder (BD) presents complex diagnostic and therapeutic challenges, especially with evolving definitions and the increasing recognition of mixed features. This session will review the clinical impact of changes across DSM editions, helping clinicians more accurately identify BD-I, BD-II, MDD, and related mood disorders in line with current guidelines. Attendees will examine the limitations of traditional treatment approaches and explore the mechanisms, indications, and latest data on emerging therapies for bipolar depression, mania, and mixed states. Practical strategies for personalized care planning, treatment monitoring, and shared decision-making will also be discussed to support improved outcomes for patients across the bipolar spectrum. Supported by an educational grant from Intra-Cellular Therapies, Inc.

Major depressive disorder (MDD) remains a leading cause of disability worldwide, with many patients experiencing limited response to conventional antidepressants, particularly when anhedonia is present. This session will explore key challenges in current MDD management and provide practical approaches to enhance detection and assessment of anhedonia in clinical settings. Attendees will also examine the mechanisms of action and latest clinical data on emerging monotherapies that hold promise for improving outcomes beyond traditional treatment paradigms. This session will equip psychiatric professionals with forward-looking, actionable strategies to optimize care for individuals with MDD. Supported by an educational grant from Axsome Therapeutics, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Lisa Marsch, PhD; Jade Wu, PhD, DBSM

This presentation is provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN; Ann Childress, MD; Desiree Matthews, PMHNP-BC

This presentation is provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Greg Mattingly, MD; Rakesh Jain, MD, MPH

This presentation is provided by Axsome Therapeutics, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Brittany Albright, MD, MPH; Andrew Cutler, MD; Mark, Patient

This presentation is provided by Johnson & Johnson.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Richard Jackson, MD; Rachel, Patient Ambassador

This presentation is provided by Teva Pharmaceuticals USA, Inc.

Persistent symptom burden, functional impairment, and adverse effects from current therapies highlight the ongoing challenges in schizophrenia management. This session will delve into the emerging role of muscarinic acetylcholine receptor activation as a novel therapeutic approach offering new hope for patients. Attendees will gain a deeper understanding of the underlying science, review the latest clinical data on approved and investigational muscarinic modulators, and explore strategies to effectively incorporate these agents into clinical practice. This evidence-driven discussion will empower psychiatric professionals with practical tools to optimize outcomes for individuals living with schizophrenia. Supported by an educational grant from Bristol-Myers Squibb.

Tardive dyskinesia (TD) remains a complex and often underdiagnosed movement disorder, particularly in patients with longstanding psychiatric conditions. This clinically focused session will equip psychiatry clinicians with practical tools to enhance TD screening, assessment, and ongoing monitoring—including the use of validated rating scales and telemedicine approaches. Attendees will refine their diagnostic skills by distinguishing TD from other movement disorders and review the latest clinical data on vesicular monoamine transporter 2 (VMAT-2) inhibitors. The session will also provide a comparative look at available VMAT-2 inhibitors, helping clinicians make informed treatment decisions tailored to the needs of patients with challenging or refractory presentations. Supported by educational grants from Neurocrine Biosciences, Inc. and Teva Pharmaceuticals, USA, Inc.

Long-term stability in bipolar disorder requires more than medication—early intervention, proactive relapse prevention, and psychosocial therapies are essential. This session will highlight evidence-based strategies to maintain stability, prevent mood episode recurrence, and enhance overall functioning. Faculty will discuss medication adherence strategies, early warning sign monitoring, and integrating psychosocial interventions to support long-term recovery.

Session developed in partnership with the Depression and Bipolar Support Alliance.

Telehealth has revolutionized psychiatric care, but what’s next? As regulations shift, digital tools advance, and hybrid care models evolve, clinicians must stay ahead of best practices, prescribing challenges, and new technology-driven solutions. This session will explore the current landscape and future of virtual mental health treatment, offering practical strategies for optimizing patient care, navigating policy updates, and integrating emerging innovations into telepsychiatry practice.

Suicide prevention requires more than just risk assessment—it demands a proactive, comprehensive approach that integrates screening, intervention, and follow-up care across diverse clinical settings. This session will explore evidence-based suicide prevention frameworks, including validated risk assessment tools, safety planning strategies, and best practices for continuity of care. Faculty will discuss how to translate research into real-world clinical workflows, ensuring that suicide prevention is actionable, accessible, and sustainable in daily practice.

Session developed in partnership with the American Foundation for Suicide Prevention (AFSP).

With ongoing conversations about stimulant use, medication availability challenges, and a growing focus on comprehensive care, clinicians are adapting how they treat ADHD. This session will explore the current landscape of ADHD treatment, offering practical strategies for navigating medication shortages while ensuring continuity of care. Faculty will emphasize holistic approaches that combine pharmacologic treatments, behavioral strategies, and peer support, providing attendees with flexible treatment plans that align with emerging trends and patient needs.

Insomnia is one of the most common yet underdiagnosed conditions in psychiatric practice, often exacerbating mood, anxiety, and psychotic disorders. This session will provide a foundational approach to insomnia assessment and treatment, helping psychiatrists navigate the bidirectional relationship between sleep and mental health. Faculty will explore key diagnostic considerations, pharmacologic and non-pharmacologic interventions, and practical strategies for integrating sleep-focused care into psychiatric practice.

Session developed in partnership with the Sleep Research Society Foundation (SRSF).

Coffee will be served in the Ballroom 20 Foyer.

The landscape of mood disorder research is rapidly evolving, with new discoveries in neurobiology, treatment innovation, and diagnostic frameworks reshaping clinical practice. This session will showcase research from the past year, featuring expert analysis alongside selected poster presenters unveiling emerging data. Faculty will highlight key takeaways from recent clinical trials and emerging trends in pharmacologic and non-pharmacologic interventions, offering insight into how these discoveries may influence the future of mood disorder treatment.

As psychedelics emerge as potential game-changers in psychiatric treatment, a key debate remains: Are their therapeutic benefits driven by the psychedelic experience itself, or do they work through non-conscious neurobiological mechanisms? This session will explore the latest research on psychedelic-assisted therapy, neuroplasticity, and drug development, examining how this question is shaping the future of psychedelic medicine. Faculty will discuss the implications for clinical practice, drug design, and optimizing treatment protocols, helping clinicians navigate where the field is headed and what it means for patient care.

Understanding billing and coding is essential for psychiatrists to ensure accurate reimbursement, regulatory compliance, and financial sustainability—yet many providers receive little formal training in this area. This session will provide up-to-date guidance on CPT codes, documentation best practices, and strategies to optimize reimbursement in both private practice and institutional settings. Faculty will also address common coding errors, telehealth billing updates, and best practices for working with insurers to minimize denials and maximize efficiency.

Determining when to initiate pharmacotherapy versus emphasizing behavioral and lifestyle interventions is a key challenge in ADHD treatment. This session will explore how clinicians can make informed first-line treatment decisions, considering symptom severity, patient preference, and co-occurring conditions. Faculty will discuss the role of stimulant and non-stimulant medications, alongside evidence-based behavioral strategies, coaching, and environmental modifications to create personalized, flexible treatment plans that optimize long-term outcomes.

Join your peers in the Exhibit Hall to engage and learn about available pharmaceuticals and devices for your practice. Hors d’oeuvres and beverages available.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Jonathan Meyer, MD

This presentation is provided by Intra-Cellular Therapies, Inc.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Rakesh Jain, MD, MPH; Brooke Kempf, PMHNP-BC

This presentation is provided by Johnson & Johnson.

Bipolar disorder frequently coexists with anxiety disorders, substance use disorders, metabolic syndrome, and other psychiatric and medical conditions, creating challenges in diagnosis and treatment. This session will focus on evidence-based strategies to manage co-occurring conditions while maintaining mood stability. Faculty will discuss medication selection, risk-benefit considerations, and behavioral interventions to optimize care for complex patients.

Session developed in partnership with the Depression and Bipolar Support Alliance.

Emerging neurobiological research suggests that Borderline Personality Disorder (BPD) may be better understood as a neurodevelopmental or spectrum-based condition, rather than a fixed personality disorder. This session will explore how shifting conceptual frameworks impact diagnosis and treatment, including transdiagnostic approaches, novel pharmacologic strategies, and neuromodulation interventions. Faculty will also discuss the growing emphasis on early identification and intervention in adolescents and young adults, aiming to prevent long-term impairment and improve patient outcomes.

Treating ADHD in high-risk populations—such as individuals with substance use disorders (SUDs), mood instability, or poor treatment adherence—requires a nuanced approach. This interactive, case-based session will challenge expert faculty to solve real-world dilemmas in ADHD management, including prescribing challenges, psychoeducation strategies, and the role of digital therapeutics. Attendees will gain practical, evidence-based solutions to improve outcomes in complex patient populations.

Disasters—whether natural, environmental, or human-made—can have profound and lasting psychiatric consequences for both affected individuals and frontline responders. This session will explore the evolving role of disaster psychiatry, including acute crisis interventions, trauma-informed care, and the long-term psychiatric impact of mass trauma. Faculty will present real-world case studies and discuss strategies for addressing community-wide anxiety, PTSD, and disaster-induced psychiatric conditions, ensuring that mental health professionals are equipped to respond effectively in times of crisis.

Fertility challenges, reproductive treatments, and perinatal loss can significantly impact mental health, relationships, and identity. This session will explore the psychological effects of fertility treatments, the grief and trauma associated with perinatal loss, and how clinicians can provide compassionate, evidence-based mental health support. Faculty will discuss screening for mood and anxiety disorders, addressing grief in a therapeutic framework, and supporting women and families throughout the reproductive journey.

Session developed in partnership with the International Society of Reproductive Psychiatry (ISRP).

Coffee will be served in the Ballroom 20 Foyer.

Partial response to antidepressant therapy remains a common and challenging barrier in the treatment of major depressive disorder (MDD), often compromising long-term recovery and patient well-being. This session will explore the clinical significance of partial response and its impact on relapse risk, daily functioning, and quality of life. Attendees will gain practical insights into optimizing existing treatments through dose adjustments and will examine the latest evidence supporting augmentation versus switching strategies—including the role of precision serotonin receptor modulators. Emphasizing a patient-centered approach, this session will empower clinicians to move beyond symptom reduction and toward functional recovery and remission-focused care. Supported by an educational grant from Takeda Pharmaceuticals, U.S.A.

Excessive daytime sleepiness (EDS) and obstructive sleep apnea (OSA) are frequently overlooked contributors to poor psychiatric outcomes, compounding cognitive, mood, and functional impairments. This session will explore the high prevalence of EDS and its psychiatric comorbidities, underscoring the critical role of psychiatry clinicians in recognizing and addressing these sleep-related conditions. Attendees will gain practical strategies to identify EDS, screen for underlying OSA, and initiate timely referrals to sleep specialists. The session will also examine emerging treatments for EDS and OSA, including novel and investigational agents, offering insight into how they compare with traditional therapies and their potential to enhance psychiatric care. Supported by an educational grant from Axsome Therapeutics, Inc. Developed in partnership with the Sleep Research Society Foundation.

Long-acting injectable antipsychotics (LAIs) offer a vital opportunity to improve treatment continuity and outcomes in schizophrenia, yet they remain underutilized in clinical practice. This unique, interactive session combines didactic learning with hands-on practice preparing, and administering LAIs, role-play simulations to improve motivational interviewing skills, and self-paced learning, all designed to enhance treatment and improve patient outcomes. Supported by educational grants from Alkermes, Inc. and Teva Pharmaceuticals, USA, Inc.

Heavy hors d'oeuvres will be served. Food is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure admission. No CE credits are offered at these programs.

The Poster Lunch & Learn is sponsored by Teva Pharmaceuticals USA, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Andrew Cutler, MD; Dan Fulford, PhD; Dawn I. Velligan, PhD

This presentation is provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Todd Broder, MD; Craig Chepke, MD, DFAPA; Erin Crown, MHS, PA-C, CAQ-Psychiatry; Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

This presentation is provided by Otsuka America Pharmaceutical, Inc. and Lundbeck.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Greg Mattingly, MD; Rebecca Kraus Barbee, PA-C, CAQ-Psych

This presentation is provided by Neurocrine Biosciences, Inc.

Join your peers in the Exhibit Hall and learn about available pharmaceuticals and devices for your practice. Take part in the Poster Pavilion to review relevant, cutting-edge research, keep up-to-date on innovative projects and programs, and learn from your colleagues in this peer-to-peer educational format.

Join leading psychiatrists and researchers for an engaging panel discussion exploring the complex relationship between sleep and psychiatric disorders. This session will cover the latest FDA-approved therapies, emerging innovations in sleep medicine, and practical strategies for improving patient outcomes.

Complementing the panel, the Sleep Scientific Discovery Hub will feature a curated collection of scientific posters highlighting groundbreaking research and therapies in sleep and psychiatry. Join us in the Exhibit Hall Theater (across from the 1200 aisle) for this unique opportunity to interact with new findings and thought leaders driving progress at the intersection of sleep and mental health.

Moderators: Philip Gehrman, Ph.D., CBSM, FAASM; Rakesh Jain, MD, MPH

Panelists: Jed Black, MD; Craig Chepke, MD, DFAPA; Andrew Cutler, MD; Logan Schneider, MD

The Sleep Research Panel & Scientific Discovery Hub is sponsored by Alkermes, Axsome Therapeutics, Inc., Jazz Pharmaceuticals, Inc., and Takeda.

Effectively engaging acutely psychotic patients requires specialized communication strategies to build trust and facilitate therapeutic rapport. This session will explore best practices for overcoming engagement barriers, with a focus on adapting interpersonal dynamics to address paranoia, limited insight, and social withdrawal. Attendees will gain practical tools to enhance assessment, foster cooperation, and lay the foundation for long-term alliance and effective treatment planning.

ADHD is increasingly recognized across adolescence and adulthood, yet late-onset and overlooked cases—particularly among high-performers—remain underdiagnosed. With an expanding range of medication options, clinicians must navigate agent selection, dosage optimization, diversion risks, and ADHD management in complex psychiatric populations. This session will provide practical strategies for diagnosing and treating ADHD across adulthood, with a focus on real-world prescribing, combination therapy, and individualized care considerations.

Losing a loved one to suicide brings an especially challenging, requiring understanding of bereavement and grief as well as the response to a loved one’s death by suicide. Suicide bereavement is a risk factor for prolonged grief disorder (PGD. This session will describe the syndrome of prolonged grief disorder (PGD) and common comorbidities in suicide loss survivors, providing clinicians with principles and procedures used in evidence-based treatment approaches, including prolonged grief therapy (PGT), cognitive-behavioral strategies and other promising approaches. In addition, faculty will briefly discuss the use of medications such as SSRIs, SNRIs, and other adjunctive treatments after suicide bereavement.

Session developed in partnership with the American Foundation for Suicide Prevention (AFSP).

Over-the-counter psychoactive substances like kratom, tianeptine (“gas station heroin”), phenibut, and synthetic cannabinoids are increasingly accessible at gas stations, convenience stores, and online. Though marketed as “natural” or “legal” alternatives, these substances can lead to dependence, withdrawal syndromes, drug interactions, and psychiatric destabilization. This session will equip clinicians with practical tools to recognize, screen for, and manage patients using these emerging substances, addressing both acute toxicity and long-term treatment considerations.

Psychotherapy is often overlooked in geriatric care, yet it remains a crucial intervention for depression, anxiety, and adjustment disorders in aging patients. This session will explore how to adapt CBT, IPT, and other therapies for older adults while considering cognitive changes and life stage challenges.

Session developed in partnership with the American Association for Geriatric Psychiatry (AAGP).

Coffee will be served in the Ballroom 20 Foyer.

Clozapine remains the gold standard for treatment-resistant schizophrenia, yet its use is often limited by strict monitoring requirements, side effect concerns, and prescribing complexities. This session will provide a deep dive into the benefits, risks, and practical challenges of clozapine therapy, exploring strategies for initiating treatment, managing side effects, and ensuring adherence. Faculty will discuss real-world cases and expert recommendations to help clinicians navigate this essential but demanding medication.

Early diagnosis and intervention are key to optimizing outcomes in Obsessive-Compulsive Disorder (OCD). This session will provide a structured, evidence-based approach to managing OCD, focusing on the critical first patient encounters. Faculty will explore first-line pharmacologic options, optimizing medication use, and integrating behavioral therapies, while also addressing common early treatment challenges and strategies for improving adherence.

Social media is both a lifeline and a liability for adolescent mental health—it can provide community and connection for those struggling in their immediate environment, yet also fuel anxiety, depression, and self-esteem issues. This session will explore the nuanced relationship between digital engagement and mental well-being, highlighting both the protective and risk factors associated with social media use. Faculty will provide practical strategies to help clinicians guide young patients toward healthy digital habits while mitigating potential harm.

Menopause marks a significant hormonal and life transition, often bringing mood disturbances, cognitive changes, and increased vulnerability to depression and anxiety. This session will explore the intersection of menopause and mental health, focusing on hormonal influences, evidence-based treatment strategies, and lifestyle interventions to support emotional well-being. Faculty will discuss when to consider hormone therapy, the role of antidepressants, and non-pharmacologic approaches, helping clinicians develop comprehensive treatment plans for menopausal patients.

Session developed in partnership with the International Society of Reproductive Psychiatry (ISRP).

Join your peers in the Exhibit Hall and learn about available pharmaceuticals and devices for your practice. Take part in the Poster Pavilion to review relevant, cutting-edge research, keep up-to-date on innovative projects and programs, and learn from your colleagues in this peer-to-peer educational format. Find out which posters were selected for the award ceremony taking place tomorrow Saturday, September 20th from 6:00 PM - 7:15 in the Sail Pavilion!

Through our continued partnership with the American Foundation for Suicide Prevention, we will host an Out of the Darkness Community Walk at this year’s Psych Congress in San Diego. All Psych Congress attendees are encouraged to participate. While donations are appreciated, there is no fundraising requirement to participate. Visit afsp.org/psychcongress to make a donation.
Walk Route Information
Kick off the walk with us at the San Diego Convention Center, which will then continue to the Psych Congress Networking Reception at the San Diego Wine and Culinary Center. Join us for this meaningful walk in support of mental health and suicide prevention and seamlessly transition into an evening of connection and community.

This year's Psych Congress AFSP Out of the Darkness Walk is provided by Bristol Myers Squibb.

Join colleagues, Psych Congress faculty, and members of the Steering Committee at the San Diego Wine & Culinary Center.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Rakesh Jain, MD, MPH

This presentation is provided by Otsuka Precision Health, Inc.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Roger S. McIntyre, MD, FRCPC

This presentation is provided by Alkermes.

Breakfast will be served. Seating is limited to 50 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat.

Benzodiazepines remain widely prescribed for anxiety, insomnia, and acute agitation, yet their potential for dependence, withdrawal, and long-term cognitive risks has led to increased scrutiny. This session will explore the appropriate role of benzodiazepines in psychiatric practice, addressing when and how to use them safely, tapering strategies, and when to consider alternative treatment options. Faculty will examine complex cases, including patients with comorbid substance use, long-term dependence, and high-risk prescribing scenarios.

Most criminal behavior is not due to mental illness. However, in those cases where there is a link, the question of whether a belief is a delusion – and if so, how that delusion impacts criminality – can become paramount. This session will explore the nuances between a subcultural belief, an extreme overvalued belief, and a delusion. It will then discuss how delusional beliefs can impact criminal behavior, competence to stand trial, and criminal responsibility – and the unique outlook that forensic psychiatrists have on the treatment of delusions. Faculty will examine real world cases, forensic evaluation and treatment strategies, and legal implications, providing clinicians with tools to identify, assess, and testify about the presence or absence of a delusion in criminal justice involved individuals.

Premenstrual Dysphoric Disorder (PMDD) is more than severe PMS—it’s a disabling mood disorder with distinct neurobiological underpinnings. This session will delve into the latest research on the pathophysiology of PMDD, including its links to hormone sensitivity, serotonin function, and neurosteroid activity. Faculty will explore emerging treatments beyond SSRIs and birth control, including neuromodulation, GABA-targeted therapies, and precision medicine approaches. Attendees will gain practical strategies for diagnosing, treating, and supporting patients with PMDD.

Session developed in partnership with the International Society of Reproductive Psychiatry (ISRP).

Individuals with substance use disorders (SUDs) face a significantly elevated risk of suicide, yet their care often falls between psychiatric and addiction treatment systems. This session will explore the complex interplay between substance use and suicidality, focusing on risk assessment, intervention strategies, and integrating suicide prevention into SUD treatment. Faculty will discuss evidence-based approaches, including medication-assisted treatment (MAT), crisis intervention, harm reduction, and relapse prevention, to support patients at the intersection of addiction and mental health crises.

Session developed in partnership with the American Foundation for Suicide Prevention (AFSP).

For patients with major depressive disorder (MDD), first-line treatment decisions require careful consideration of symptom severity, functional impairment, and patient-specific factors. This session will examine when to initiate pharmacotherapy versus prioritizing psychotherapy, exercise, sleep interventions, and other lifestyle modifications. Faculty will discuss how to identify patients most likely to benefit from non-pharmacologic approaches alone, when combination therapy is appropriate, and how to adapt treatment plans over time to support recovery and relapse prevention.

Session developed in partnership with the Depression and Bipolar Support Alliance.

Coffee will be served in the Ballroom 20 Foyer.

Sleep-wake disturbances are among the most prevalent and impairing symptoms in major depressive disorder (MDD), yet current treatment decisions often rely on simplistic distinctions between “sedating” and “activating” antidepressants. This session will examine the potential of insomnia and hypersomnia as clinically useful biomarkers to guide more precise, effective interventions. Attendees will explore the limitations of traditional treatment approaches and review the latest clinical evidence on emerging pharmacotherapies targeting sleep-wake dysfunction in MDD. Emphasis will be placed on improving the assessment of sleep-wake symptoms in psychiatric practice and aligning treatment strategies with individual patient needs. Supported by an educational grant from Johnson & Johnson. Developed in partnership with the Sleep Research Society Foundation.

As the landscape of mental health treatment continues to evolve, prescription digital therapeutics (PDTs) are emerging as powerful tools to complement traditional psychiatric interventions. This session will explore the latest evidence supporting the use of PDTs across a range of psychiatric conditions, highlighting their role in improving symptom control, enhancing treatment adherence, and driving better patient outcomes. Attendees will gain practical strategies for integrating these digital interventions into clinical workflows to address unmet therapeutic needs, especially when current treatments fall short. Through case-based discussions and real-world insights, participants will leave equipped to incorporate PDTs into their practice with confidence and purpose. This program is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
John Rush, MD; Charles Conway, MD

This presentation is provided by LivaNova.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Craig Chepke, MD, DFAPA

This presentation is provided by Axsome Therapeutics, Inc.

Lunch will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Gus Alva, MD, DLFAPA

This presentation is provided by Otsuka America Pharmaceutical, Inc. and Lundbeck.

Join your peers in the Exhibit Hall and learn about available pharmaceuticals and devices for your practice. Take part in the Poster Pavilion to review relevant, cutting-edge research, keep up-to-date on innovative projects and programs, and learn from your colleagues in this peer-to-peer educational format.

Seating is limited to 150 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Patrick Vollmar - Executive Director, Neuroscience Strategy Lead; Carey Martin, FNP, PHMNP, DNP; Arun Nagrenda, Ph.D.; Kelly Overdorf, Care Partner

This presentation is provided by Bristol Myers Squibb.

Social Anxiety Disorder (SAD) is often misdiagnosed or undertreated, leading to chronic impairment if not addressed early. This session will provide a structured, evidence-based approach to diagnosing and managing SAD in its early stages, emphasizing first-line pharmacologic treatment, psychotherapy, and functional improvement strategies. Faculty will also explore the impact of common comorbidities such as depression, avoidant personality traits, ADHD, and substance use disorders, which frequently complicate treatment.

Complex bipolar disorder presents unique challenges, particularly in cases of rapid cycling, mixed episodes, and co-occurring conditions such as ADHD, MDD, and personality disorders. This session will provide a practical, evidence-based approach to diagnosing and treating difficult-to-stabilize patients, with a focus on medication optimization, polypharmacy management, and psychosocial interventions. Experts will discuss cutting-edge strategies to enhance treatment response and long-term stability.

For many patients with treatment-resistant depression, OCD, and other psychiatric conditions, traditional medications alone are not enough. This session will explore the growing role of interventional psychiatry, including TMS, ketamine/esketamine, ECT, and emerging neuromodulation techniques. Faculty will discuss patient selection, optimizing outcomes, and integrating interventional strategies with standard psychiatric care to improve long-term recovery and functional outcomes.

From psilocybin and MDMA-assisted therapy to novel psychedelic compounds, the field of psychedelic psychiatry is rapidly evolving. But what’s real, what’s hype, and where is the science leading us? This session will provide a comprehensive update on recent clinical trials, regulatory developments, and emerging indications for psychedelic-assisted therapy. Faculty will explore current best practices, safety considerations, and the challenges of integrating psychedelics into mainstream psychiatric care.

Excessive daytime sleepiness and wakefulness disorders are often overlooked in psychiatric settings, yet they can significantly impact mood, cognition, and treatment outcomes. This session will provide a foundational guide to understanding and managing hypersomnia syndromes, narcolepsy, and circadian rhythm disorders, with a focus on their overlap with psychiatric conditions. Faculty will explore assessment strategies, pharmacologic treatment options, and the role of wake-promoting agents in psychiatric practice.

Session developed in partnership with the Sleep Research Society Foundation (SRSF).

Coffee will be served in the Ballroom 20 Foyer.

Neurodevelopmental disorder research is advancing at an unprecedented pace, providing new insights into genetics, brain network function, and novel interventions for conditions like ADHD and autism. This session will highlight breaking research and key studies from the past year, featuring expert analysis alongside selected poster presenters unveiling emerging data. Faculty will discuss the latest treatment strategies, innovative behavioral interventions, and digital therapeutics, offering practical insights into how these discoveries may transform patient care.

How do you manage treatment-resistant anxiety, crisis-level distress, and high-stress patients who don’t respond to standard interventions? This session challenges expert faculty to navigate real-world complex cases of anxiety disorders, debating diagnostic dilemmas, crisis intervention strategies, and long-term stabilization approaches. Attendees will gain practical, case-based insights on how to refine treatment strategies when conventional approaches fail.

Managing suicide risk often involves complex clinical decisions, requiring clinicians to balance patient autonomy with the need for safety. This session will explore key ethical challenges, including cultural considerations and biases in risk assessment, when to override autonomy for patient protection, and the duty to warn while maintaining confidentiality. Faculty will also discuss ethical considerations in hospitalization decisions, ensuring clinicians can navigate these dilemmas while respecting patient rights and optimizing care outcomes.

Session developed in partnership with the American Foundation for Suicide Prevention (AFSP).

Complex PTSD (C-PTSD) presents distinct clinical challenges, requiring a nuanced diagnostic approach and targeted interventions beyond standard PTSD treatment. This session will explore the key differences between PTSD and C-PTSD, the neurobiological and psychological impact of prolonged trauma, and evidence-based strategies for treatment. Faculty will provide practical guidance on managing emotional dysregulation, dissociation, and interpersonal difficulties, which are hallmarks of C-PTSD, and discuss the latest innovations in trauma-informed

Join the Psych Congress Steering Committee, attendees, and peers for a poster reception and announcements of awards with live music, hors d'oeuvres, and beverages.

The Poster Reception & Awards Ceremony is sponsored by Axsome Therapeutics, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Johnson & Johnson. Sponsorships support the Poster Reception only. The Awards Ceremony is independently organized and not part of this sponsorship.

Breakfast will be served. Seating is limited to 200 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat.

Major depressive disorder (MDD) in older adults is frequently underrecognized and undertreated, despite its profound impact on quality of life and overall health outcomes. This session will address the unique challenges of diagnosing and managing MDD in this population, including the influence of age-related biological changes and comorbid conditions. Attendees will explore the latest clinical and real-world evidence on both conventional antidepressants and emerging multimodal agents, with an emphasis on tailoring treatment to individual needs. Practical strategies for patient-centered care, including shared decision-making with patients and caregivers, will be discussed to support optimal outcomes.

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A.

Developed in partnership with Caregiver Action Network.

Anger and irritability are often overlooked in psychiatric care, despite their prevalence and impact across mood, anxiety, personality, and neurodevelopmental disorders. This session will explore the neurobiology of anger, its role in psychiatric presentations, and evidence-based strategies for assessment and management. Faculty will provide practical guidance on pharmacologic and psychotherapeutic approaches, offering tools to help clinicians better address these neglected emotions and improve patient outcomes.

Early intervention in First-Episode Psychosis (FEP) is crucial for long-term outcomes. This session will provide a structured, evidence-based approach to the identification and management of FEP, focusing on critical first patient encounters following diagnosis. Faculty will discuss pharmacologic and psychosocial interventions, relapse prevention, and strategies for care coordination, ensuring that clinicians can deliver effective early intervention to support long-term recovery and functional stability.

Developed in partnership with Schizophrenia & Psychosis Action Alliance.

Substance use in older adults is on the rise, yet it is frequently overlooked. This session will examine the growing prevalence of alcohol and cannabis use in aging populations, how to recognize substance-related cognitive impairment, and strategies for effective intervention.

Session developed in partnership with the American Association for Geriatric Psychiatry (AAGP).

Coffee will be served in the Ballroom 20 Foyer.

For patients with treatment-resistant depression (TRD), conventional monoaminergic antidepressants often fall short, prolonging the burden of illness and limiting recovery. This session will explore the neurobiological rationale for shifting beyond traditional targets toward glutamatergic and neuromodulation-based therapies. Attendees will evaluate the latest clinical and real-world evidence supporting these emerging treatments and gain insights into their mechanisms of action, safety, and efficacy. The session will also focus on translating this evidence into practice, equipping clinicians with tools to develop personalized, guideline-aligned treatment plans rooted in shared decision-making and patient-centered care. Supported by an educational grant from Johnson & Johnson.

Excessive sleepiness in psychiatric patients is often misattributed to depression, medication side effects, or treatment resistance—when in fact, underlying sleep-wake disorders such as narcolepsy or idiopathic hypersomnia (IH) may be the root cause. This session will help psychiatry clinicians recognize the high prevalence and diverse presentations of hypersomnolence in mental health populations. Attendees will learn how to implement effective screening strategies, differentiate among key sleep-wake disorders (OSA, NT1, NT2, IH), and make appropriate referrals to sleep specialists. The session will also explore current and emerging treatments for hypersomnolence with an emphasis on cardiovascular safety, enabling clinicians to provide more accurate diagnoses and tailored, heart-conscious care. This program is supported by an independent medical education grant from Jazz Pharmaceuticals. Developed in partnership with the Sleep Research Society Foundation.

Lunch will be served. Seating is limited to 250 attendees and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs.

Presenter(s):
Andrew Cutler, MD; Christoph Correll, MD; Wyatt Forte; Denise Forte, JD

This presentation is provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Generalized Anxiety Disorder (GAD) is more prevalent than ever, influenced by rising societal stressors and evolving neurobiological insights. This session will explore why cultural and technological shifts are driving increased rates of GAD, how neurobiology, stress systems, and rumination mechanisms shape the disorder, and what new treatment approaches are emerging to improve patient outcomes.

Early detection of eating disorders (EDs) in children and adolescents is critical for preventing long-term physical and psychological harm, yet many cases go unrecognized or misattributed to other mental health concerns. This session will explore practical strategies for early screening and intervention, emphasizing the unique presentations of EDs in younger patients. Faculty will also discuss emerging diagnostic categories, such as Avoidant/Restrictive Food Intake Disorder (ARFID), and the importance of multidisciplinary collaboration in treatment.

Substance use during pregnancy and the postpartum period presents unique clinical, ethical, and therapeutic challenges. This session will explore current trends in perinatal substance use, including commonly encountered substances such as cannabis and stimulants, and their implications for maternal and fetal health. Faculty will discuss strategies for screening, engaging patients in care, and delivering evidence-based treatment during pregnancy. The session will also highlight approaches to prevent relapse and support recovery in the postpartum period through trauma-informed care, coordination with obstetric teams, and long-term psychiatric support.

Session developed in partnership with the International Society of Reproductive Psychiatry (ISRP).

Whole-person care means more than just symptom management—it’s about empowering recovery and resilience. This closing panel will discuss how blending pharmacologic treatment with lifestyle, psychosocial, and complementary strategies leads to sustainable mental health outcomes. The panel will explore current debates on medication optimization, avoiding over-reliance on prescriptions, and how non-pharmacologic approaches can enhance psychiatric care without dismissing the value of medications.